{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:18:39Z","timestamp":1773307119247,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.beha.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T03:16:09Z","timestamp":1415675769000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["More is better: Combination therapies for myelodysplastic syndromes"],"prefix":"10.1016","volume":"28","author":[{"given":"Moshe C.","family":"Ornstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2014.11.002_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib2","series-title":"SEER cancer statistics review 1975\u20132009: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML)","author":"National Caner Institute","year":"2010"},{"key":"10.1016\/j.beha.2014.11.002_bib3","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/aje\/kwp074","article-title":"Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort","volume":"169","author":"Ma","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.beha.2014.11.002_bib4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/djs411","article-title":"Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis","volume":"104","author":"Schnatter","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.beha.2014.11.002_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/asheducation-2013.1.504","article-title":"Prognostic models in myelodysplastic syndromes","author":"Bejar","year":"2013","journal-title":"Am Soc Hematol Ed Program"},{"key":"10.1016\/j.beha.2014.11.002_bib6","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib7","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower-risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib10","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO.2012.48.0764","volume":"31","author":"Voso","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2014.11.002_bib12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib13","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.exphem.2007.09.007","article-title":"Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome","volume":"35","author":"Kerbauy","year":"2007","journal-title":"Exp Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2014.11.002_bib14","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","article-title":"DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes","volume":"28","author":"Shen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib17","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2014.11.002_bib18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2004.00363.x","article-title":"Somatic point mutations in RUNX1\/CBFA2\/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia","volume":"74","author":"Steensma","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.11.002_bib21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.11.002_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A\u00a0validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin\u00a0+\u00a0granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib23","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.beha.2014.11.002_bib24","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0145-2126(07)70459-9","article-title":"Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes","volume":"31","author":"Malcovati","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.11.002_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.11.002_bib26","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib27","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib29","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A\u00a0randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib30","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2014.11.002_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib33","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.11.002_bib34","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib35","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2014.11.002_bib37","first-page":"557","article-title":"Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors","volume":"10","author":"Schneider-Stock","year":"2007","journal-title":"IDrugs"},{"key":"10.1016\/j.beha.2014.11.002_bib38","first-page":"214143","article-title":"Myelodysplastic syndrome and histone deacetylase inhibitors: \u201cto be or not to be acetylated\u201d?","volume":"2011","author":"Stintzing","year":"2011","journal-title":"J\u00a0Biomed Biotechnol"},{"issue":"31","key":"10.1016\/j.beha.2014.11.002_bib39","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib40","doi-asserted-by":"crossref","first-page":"e53766","DOI":"10.1371\/journal.pone.0053766","article-title":"Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms","volume":"8","author":"Silva","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2014.11.002_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","article-title":"Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid","volume":"29","author":"Yang","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.11.002_bib42","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2014.11.002_bib43","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib44","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13148-011-0031-9","article-title":"Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid","volume":"2","author":"Kuendgen","year":"2011","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.beha.2014.11.002_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2014.11.002_bib47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.1065173","article-title":"Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor","volume":"295","author":"Di Croce","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beha.2014.11.002_bib48","first-page":"429","article-title":"5' azacitidine in combination with valproic acid induces complete remissions in patients with high risk leukaemia but does not eradicate clonal leukaemic stem\/progenitor cells","volume":"94","author":"Craddock","year":"2009","journal-title":"Haematol (EHA Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib49","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib50","article-title":"A\u00a0phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of the study 6898 of the New York Cancer Consortium","volume":"122","author":"Silverman","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib51","article-title":"Combination therapy with mocetinostat, an oral, spectrum-selective histone deacetylase (HDAC) inhibitor, and 5-azaciditine: indication of clinical activity in MDS","volume":"122","author":"Garcia-Manero","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib52","article-title":"Determination of the maximum tolerated dose of panobinostat in combination with a 5-Day schedule of azacitidine in high-risk myelodysplastic syndrome and acute myeloid leukemia: planned interim analysis of a phase Ib\/II study","volume":"118","author":"Tan","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib53","article-title":"Very high rate of CLinical and cytogenetic response with the combination of histone deacetylase inhibitor pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome","volume":"120","author":"Quintas-Cardama","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib54","article-title":"Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905","volume":"116","author":"Prebet","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib55","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21891","article-title":"Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"86","author":"Sekeres","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2014.11.002_bib57","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib58","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.11.002_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/leu.2013.26","article-title":"Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study","volume":"27","author":"Platzbecker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.11.002_bib61","article-title":"A\u00a0phase I-II study of the efficacy and safety of lenalidomide (LEN) combined to azacitidine (AZA) in higher risk MDS and AML with del 5q \u2013 a study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"122","author":"Ades","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib62","article-title":"A\u00a0phase II study of the combination of azacitidine and lenalidomide in patients (pts) with higher risk myelodysplastic syndromes (MDS)","volume":"122","author":"Garcia-Manero","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib63","article-title":"A\u00a0report on a phase 2 trial on combination therapy with lenalidomide and azacitidine in patients with non-del 5q, low risk MDS","volume":"122","author":"Shammo","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib64","article-title":"Lenalidomide (LEN) combined to intensive chemotherapy (IC) in AML and higher risk MDS with del 5q. Results of a phase I\/II study of the Groupe Francophone des Myelodysplasies (GFM)","volume":"122","author":"Ades","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib65","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/emboj\/18.5.1321","article-title":"Regulation of JNK signaling by GSTp","volume":"18","author":"Adler","year":"1999","journal-title":"Embo J"},{"key":"10.1016\/j.beha.2014.11.002_bib66","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/cdd.2010.80","article-title":"Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death","volume":"17","author":"Laborde","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.beha.2014.11.002_bib67","series-title":"Proceedings of the AACR-NCI-EORTC International Conference","article-title":"Novel ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity","author":"Ali-Osman","year":"2011"},{"key":"10.1016\/j.beha.2014.11.002_bib68","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1182\/blood-2009-01-176032","article-title":"Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome","volume":"113","author":"Raza","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.11.002_bib69","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/cncr.26469","article-title":"A\u00a0phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome","volume":"118","author":"Raza","year":"2012","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.beha.2014.11.002_bib70","article-title":"Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)","volume":"5","author":"Raza","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"Suppl.","key":"10.1016\/j.beha.2014.11.002_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/107327480601304s03","article-title":"Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes","volume":"13","author":"List","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.beha.2014.11.002_bib72","article-title":"A\u00a0phase II clinical trial of lenalidomide and prednisone in low and intermediate-1 IPSS risk, non-del (5q) MDS patients","volume":"122","author":"Komrokji","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"71","key":"10.1016\/j.beha.2014.11.002_bib73","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide","volume":"5","author":"Wang","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib74","article-title":"Efficacy and safety of romiplostin in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib75","first-page":"2","article-title":"Antibody-targeted therapy for myeloid leukemia","volume":"36","author":"Appelbaum","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2014.11.002_bib76","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","article-title":"Differences in CD33 intensity between various myeloid neoplasms","volume":"118","author":"Jilani","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2014.11.002_bib77","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.25686","article-title":"A\u00a0phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.11.002_bib78","article-title":"Phase 2 study of decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome-outcome in previously untreated patients","volume":"114","author":"Borthakur","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib79","article-title":"Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome","volume":"120","author":"Daver","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.leu.2402356","article-title":"Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study","volume":"16","author":"Deeg","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.11.002_bib81","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jcp.1041650312","article-title":"Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death","volume":"165","author":"Selleri","year":"1995","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.beha.2014.11.002_bib82","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2141.2009.08061.x","article-title":"Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept","volume":"148","author":"Scott","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib83","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2010.08145.x","article-title":"Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study","volume":"149","author":"Scott","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib84","first-page":"439","article-title":"Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines","volume":"29","author":"Liesveld","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1016\/j.beha.2014.11.002_bib85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.leukres.2010.08.021","article-title":"Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes","volume":"35","author":"Alimena","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.11.002_bib86","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2012.09153.x","article-title":"Bortezomib combined with low-dose cytarabine in intermediate-2 and high risk myelodysplastic syndromes. A phase I\/II Study by the GFM","volume":"158","author":"Natarajan-Ame","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.11.002_bib87","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2013.05.011","article-title":"Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"37","author":"Attar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.11.002_bib88","article-title":"Phase I trial of belinostat and bortezomib in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis - one year update","volume":"120","author":"Holkova","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib89","first-page":"1347","article-title":"Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline","volume":"32","author":"Fukushima","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.beha.2014.11.002_bib90","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1200\/JCO.2011.38.3265","article-title":"Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome","volume":"30","author":"Garcia-Manero","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.11.002_bib91","article-title":"Safety and efficacy of bendamustine and idarubicin in combination therapy for patient >50 with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome \u2013 results from a phase I\/II adaptive design study","volume":"120","author":"Shadman","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2014.11.002_bib92","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12185-011-0987-4","article-title":"Combination strategies in myelodysplastic syndromes","volume":"95","author":"Ornstein","year":"2012","journal-title":"Int J Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T17:02:45Z","timestamp":1598461365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1521692614000826"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.11.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"More is better: Combination therapies for myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}